TECH
Bio-Techne Corporation
NASDAQ · Healthcare · Biotechnology · US
$72.43
−0.03%Year over year
Reported trailing growth
- Revenue
- -0.4%
- EBITDA
- +58.4%
- EBIT
- +146.3%
- EPS
- +154.3%
- Free cash flow
- +2.6%
- Operating cash flow
- +1.6%
Forward estimates
Based on analyst estimates
- Revenue
- +3.9%
- EBITDA
- +40.3%
- EPS
- +75.4%
Three-year CAGR
- Revenue
- +2.2%
- EBITDA
- -9.1%
- EBIT
- -5.5%
- Net income
- -13.9%
- EPS
- -13.5%
- Free cash flow
- +6.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026